Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2016, Article ID 6810562, 14 pages
http://dx.doi.org/10.1155/2016/6810562
Review Article

Biomaterial Applications in Cell-Based Therapy in Experimental Stroke

1Inserm, U1216, BP 170, 38042 Grenoble Cedex 9, France
2Grenoble Institut des Neurosciences (GIN), Université Grenoble Alpes, 38000 Grenoble, France
3CAPES Foundation, Ministry of Education of Brazil, 70040-020 Brasília, DF, Brazil
4Institute for Frontier Medical Sciences, Department of Reparative Materials, Kyoto University, Kyoto 606-8507, Japan
5CHU Grenoble Alpes, Stroke Unit, Department of Neurology, CS 10217, 38043 Grenoble, France
6CERMAV, CNRS, CERMAV, Université Grenoble Alpes, 38000 Grenoble, France
7Cell Therapy and Engineering Unit, EFS Rhône Alpes, 464 route de Lancey, 38330 Saint-Ismier, France

Received 18 December 2015; Revised 11 March 2016; Accepted 4 April 2016

Academic Editor: Paulo Henrique Rosado de Castro

Copyright © 2016 Ligia S. B. Boisserand et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Stroke is an important health issue corresponding to the second cause of mortality and first cause of severe disability with no effective treatments after the first hours of onset. Regenerative approaches such as cell therapy provide an increase in endogenous brain structural plasticity but they are not enough to promote a complete recovery. Tissue engineering has recently aroused a major interesting development of biomaterials for use into the central nervous system. Many biomaterials have been engineered based on natural compounds, synthetic compounds, or a mix of both with the aim of providing polymers with specific properties. The mechanical properties of biomaterials can be exquisitely regulated forming polymers with different stiffness, modifiable physical state that polymerizes in situ, or small particles encapsulating cells or growth factors. The choice of biomaterial compounds should be adapted for the different applications, structure target, and delay of administration. Biocompatibilities with embedded cells and with the host tissue and biodegradation rate must be considerate. In this paper, we review the different applications of biomaterials combined with cell therapy in ischemic stroke and we explore specific features such as choice of biomaterial compounds and physical and mechanical properties concerning the recent studies in experimental stroke.